SORT BY

FILTER BY

also on other fortune lists

company facts

g500 stats

Global 500

Richard Levine—Alamy Stock Pho Alamy Stock Photo

100

Johnson & Johnson

JNJ

U.S.

The 132-year-old company, which specializes in pharmaceuticals, consumer health care, and medical devices, sells a wide array of health and beauty products including the Johnson’s Baby line, Neutrogena, Listerine, Band Aids, Tylenol, and Motrin. The company has been at the center of lawsuits concerning products that contain talc and their possible link to ovarian cancer and lung-related cancers, and has also been sued in connection with the U.S. opioid epidemic. But even amid legal conflicts and competition and pricing pressures in the industry, the company saw domestic sales increase 5.4% and international sales increase 7.4% in 2017. The company raised its sales outlook for 2018 due to the high performance of its pharmaceutical business, particularly cancer drugs.

Looking for leads, investment insights, or competitive intelligence?

CEO

Alex Gorsky

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New Brunswick, N.J.

Years on Global 500 List

18

Employees

134,000

Key Financials (Last Fiscal Year)
($ Millions)% change
Revenues ($M)$76,4506.3%
Profits ($M)$1,300.0-92.1%
Assets ($M)$157,303
Total Stockholder Equity ($M)$60,160
Profit Ratios
Profit as % of Revenues1.7%
Profits as % of Assets0.8%
Profits as % of Stockholder Equity2.2%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Johnson & Johnson

The Health Care Companies Changing the World

Why Merck, Johnson & Johnson, Humana, and others made our crop of firms doing well by doing good.

Read More →
China’s New Trade Strategy: Threatening U.S. Companies

A government newspaper targeted Apple earlier this month.

Read More →
Does J&J's Baby Powder Cause Cancer? A Jury Just Said Yes With an Enormous $4.69 Billion Penalty

J&J will appeal the verdict, which it argues is "the product of a fundamentally unfair process."

Read More →